Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

24 Apr 2019 07:00

RNS Number : 8674W
Biome Technologies PLC
24 April 2019
 

 

 

24 April 2019

 

Biome Technologies plc

("Biome", "the Company" or "the Group")

 

Trading Update

 

 

In advance of its Annual General Meeting today, Biome Technologies, a leading bioplastics and radio frequency technology business, is pleased to announce a trading update for the three months ended 31 March 2019.

 

Group revenues achieved for the first three months of the year were £2.1m, which is 11% ahead of the previous quarter (Q4 2018: £1.9m) and in line with those achieved in Q1 2018 (Q1 2018: £2.1m).

 

The Group made a small profit before interest, tax, depreciation, amortisation and share option charges in this quarter (based on unaudited management accounts).

 

The Group's cash position as at 31 March 2019 was £2.1m (31 December 2018: £2.6m), reflecting working capital movements.

 

Bioplastics Division

Revenues in the Bioplastics division for the first quarter rose significantly to £0.6m (Q1 2018: £0.4m; Q4 2018: £0.4m).

 

The improved performance was helped by both increased sales of outer packaging for the US single serve coffee market and by initial sales for a novel material for a single serve pod being launched into the nutrition market, previously reported as being under development. It is anticipated that sales for this latter application will gradually increase through the remainder of this year.

 

Progress on other projects, such as the rigid ring material and a plastic film based product for the North America market, remain on track with revenues for the rigid ring continuing to be anticipated to commence in Q2 2019 following completion of final testing.

 

Stanelco RF Technologies Division

Revenues for the first quarter of 2019 in the Stanelco RF division were £1.5m (Q1 2018: £1.7m; Q4 2018: £1.5m). The quarter was impacted positively by the delivery of multiple fibre optic furnaces which will not occur to the same extent in Q2.

 

In light of the current order book and general market outlook, the Board believes that revenues from this division for 2019 will be in line with previous guidance but more likely to be closer to those of 2017 than 2018, which was an exceptional year.

 

Outlook

2019 has commenced in an encouraging manner, particularly for the Bioplastics Division, and in line with the expectations set out in the Company's preliminary results announcement.

  

 

- Ends -

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

In 2018, the Board has adopted the following three high level KPIs for the next three years to continue its ambitious momentum:

· Compound revenue growth of 25% per annum across the Group and 40% compound revenue growth in the Bioplastics division

· Diversify the Group's turnover by product and market to ensure that no one product or end customer contributes more than 15% of revenues by 2020

· Increase investment in the Group's next generation of products by spending significantly more per annum on average than the £0.3m per annum average spend over the previous strategic objective cycle

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

#ThinkBioplastic is our digital educational platform, launched in October 2018 in response to the emerging global plastic conversation. It speaks to a wide audience, highlighting bioplastics as a leading solution among several to reduce the negative impact of plastic manufacture and disposal. Following the much acclaimed first series of short videos the second series has just been released.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTCKNDBFBKDFQB
Date   Source Headline
3rd Sep 20127:00 amRNSInterim Results
29th Aug 20127:00 amRNSPrototype Delivery for Stanelco RF Technologies
19th Jul 20127:00 amRNSInterim Trading Statement
17th Jul 20127:00 amRNSFinancing and Loan Repayment
12th Jul 20127:00 amRNSPatent Litigation Update
10th Jul 20124:40 pmRNSSecond Price Monitoring Extn
10th Jul 20124:35 pmRNSPrice Monitoring Extension
19th Jun 20127:00 amRNSLoan Facility Extension/Directorate Change
31st May 20127:00 amRNSTrading Update
15th May 20124:40 pmRNSSecond Price Monitoring Extn
15th May 20124:35 pmRNSPrice Monitoring Extension
25th Apr 20121:35 pmRNSResult of AGM
25th Apr 20127:00 amRNSTrading Update
4th Apr 20127:00 amRNSNotification of Award under the Public Equity Plan
29th Mar 20127:00 amRNSPreliminary Results
19th Jan 20127:00 amRNSPre-close Trading Statement
10th Jan 20127:00 amRNSContract for RF Technologies Business
16th Dec 20111:27 pmRNSDirector/PDMR Shareholding
6th Dec 20117:00 amRNSLoan Reclassification
4th Nov 20117:00 amRNSTrading Update
21st Oct 20114:35 pmRNSPrice Monitoring Extension
19th Sep 20117:00 amRNSSector Reclassification
1st Sep 20117:01 amRNSDirectorate Changes
1st Sep 20117:00 amRNSInterim Results
16th May 201111:07 amRNSDirector/PDMR Shareholding
9th May 20117:00 amRNSDirector/PDMR Shareholding
5th May 20112:28 pmRNSResult of AGM
5th May 20117:00 amRNSTrading Update
12th Apr 201112:22 pmRNSHolding(s) in Company
28th Mar 20114:23 pmRNSAnnual Report &Accounts for 2010 and Notice of AGM
24th Mar 20117:00 amRNSPreliminary Results
28th Feb 201112:22 pmRNSTotal Voting Rights
23rd Feb 20114:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20114:35 pmRNSPrice Monitoring Extension
17th Feb 20117:00 amRNSAppointment of Nominated Adviser & Joint Brokers
5th Nov 20107:00 amRNSTrading Update
14th Oct 20107:00 amRNSDirector/PDMR Shareholding
7th Oct 20107:00 amRNSDirectorate Change
5th Oct 20107:00 amRNSNotification of Awards under Public Equity Plan
17th Sep 20104:37 pmRNSPrice Monitoring Extension
27th Aug 20107:00 amRNSHalf Yearly Report
13th Jul 20107:55 amRNSFirst Day of Dealings on AIM
12th Jul 20107:00 amRNSChange of Name
1st Jul 201010:07 amRNSTotal Voting Rights
22nd Jun 20101:07 pmRNSResult of AGM
22nd Jun 20107:00 amRNSAnnual General Meeting & Trading Update
21st Jun 20104:41 pmRNSSch 1 update - Stanelco plc
21st Jun 20104:15 pmRNSDirector/PDMR Shareholding: Correction
15th Jun 20105:03 pmRNSDirector/PDMR Shareholding
14th Jun 201012:40 pmRNSSchedule 1 - Stanelco PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.